Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11318286 | 0.69 | KDM4E (0.49) | — | |
| SCHEMBL16432965 | 0.69 | KDM5B (0.49) | KDM5B | |
| SCHEMBL17784391 | 0.68 | KDM5B (0.43) | KDM5B | |
| SCHEMBL545036 | 0.67 | LOXL2 (0.46) | — | |
| SCHEMBL2271041 | 0.61 | — | — | |
| SCHEMBL10985858 | 0.60 | KDM5B (0.49) | KDM5BTP53 | |
| SCHEMBL9598677 | 0.60 | KDM5B (0.48) | KDM5BTP53 | |
| SCHEMBL31376518 | 0.60 | KDM5A (0.55) | KDM5B | |
| SCHEMBL6469168 | 0.60 | ADORA3 (0.57) | — | |
| SCHEMBL16376224 | 0.60 | ADORA3 (0.34) | KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509467-B2 | CGAS inhibiting triazolopyrimidone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2025-12-30 | — | — | US | claimed |
| US-20230374014-A1 | CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-23 | — | — | US | claimed |
| CN-115667265-A | CGAS-inhibiting triazolopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | claimed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | claimed |
| US-12509467-B2 | CGAS inhibiting triazolopyrimidone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2025-12-30 | — | — | US | disclosed |
| WO-2025137599-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250206738-A1 | WRN INHIBITORS | NIMBUS DISCOVERY, INC. | 2025-06-26 | — | — | US | disclosed |
| EP-4543882-A1 | MICROBIOCIDAL BICYCLIC HETEROCYCLIC CARBOXAMIDE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-04-30 | — | — | EP | disclosed |
| CN-119899191-A | 4-Butyl-2, 7-bis (2-fluorophenyl) -triazolopyrimidine-5 (4H) -one compound, and preparation method and application thereof | 青岛科技大学 | 2025-04-29 | — | — | CN | disclosed |
| CN-119899186-A | Azabicyclo derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2023247552-A1 | MICROBIOCIDAL BICYCLIC HETEROCYCLIC CARBOXAMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-12-28 | — | — | WO | disclosed |
| US-20230410950-A1 | CHEMICAL REACTION GRAPH COMPRESSION SOFTWARE, CORRESPONDING METHOD AND ASSOCIATED DATA APPLICATIONS | FIRMENICH SA (CH) | 2023-12-21 | — | — | US | disclosed |
| US-20230374014-A1 | CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4153593-A1 | CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| CN-115667265-A | CGAS-inhibiting triazolopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-0733633-B1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-5753664-A | ANTITUMOR AGENTS, PYRIMIDONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509467-B2 | CGAS inhibiting triazolopyrimidone derivatives | CGAS, STING1, IRF3 | KDM5B 4529/4885TP53 1759/4885 |
| US-20250206738-A1 | WRN INHIBITORS | WRN, BLM, RECQL | KDM5B 3660/4885TP53 5/4885 |
| US-20230374014-A1 | CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES | CGAS, GLS2, GBA3 | KDM5B 4594/4885TP53 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.